UVEAL MELANOMA TREATMENT USING SEA-CD40

1 . A method of treating uveal melanoma comprising administering a composition comprising an anti-CD40 antibody to a patient with uveal melanoma,

wherein the anti-CD40 antibody comprises: 1) a heavy chain variable region comprising an amino acid sequence of SEQ ID NO:1; 2) a light chain variable region comprising an amino acid sequence of SEQ ID NO:2; and 3) a human constant region;

wherein the human constant region comprises an N-glycoside-linked sugar chain at residue N297 (EU numbering), wherein less than 5% of N-glycoside-linked sugar chains at residue N297 (EU numbering) in the composition comprise a fucose residue; and

wherein the anti-CD40 antibody is administered at a dose of about 3 μg/kg, about 10 μg/kg, about 30 μg/kg, about 45 μg/kg, or about 60 μg/kg patient body weight.

2 . The method of claim 1 , wherein the dose is about 30 μg/kg patient body weight.

3 . The method of claim 1 or 2 , wherein the anti-CD40 antibody is administered every three weeks or every six weeks.

4 . The method of any one of claims 1 - 3 , further comprising administering a chemotherapeutic agent.

5 . The method of claim 4 , wherein the chemotherapeutic agent is gemcitabine, dacarbazine, temozolomide, paclitaxel, albumin-bound paclitaxel, or carboplatin.

6 . A method of treating uveal melanoma comprising administering 1) a composition comprising an anti-CD40 antibody; and 2) an anti-PD1 antibody or an anti-PDL1 antibody to a patient with uveal melanoma,

wherein the anti-CD40 antibody comprises: 1) a heavy chain variable region comprising an amino acid sequence of SEQ ID NO:1; 2) a light chain variable region comprising an amino acid sequence of SEQ ID NO:2; and 3) a human constant region;

wherein the human constant region comprises an N-glycoside-linked sugar chain at residue N297 (EU numbering), wherein less than 5% of the N-glycoside-linked sugar chains at residue N297 (EU numbering) in the composition comprise a fucose residue; and

wherein the anti-CD40 antibody is administered at a dose of about 3 μg/kg, about 10 μg/kg, about 30 μg/kg, about 45 μg/kg, or about 60 μg/kg patient body weight.

7 . The method of claim 6 , wherein the anti-PD1 antibody is selected from the group consisting of Pembrolizumab, Nivolumab, Cemiplimab-rwlc, Spartalizumab, AK105, Tislelizumab, Dostarlimab, MEDI0680, Pidilizumab, AMP-224, and SHR-1210.

8 . The method of claim 6 or 7 , wherein the anti-PDL1 antibody is selected from the group consisting of Atezolizumab, Durvalumab, Avelumab, SHR-1316, MEDI4736, BMS-936559/MDX-1105, MSB0010718C, MPDL3280A, or Envafolimab.

9 . The method of any one of claims 6 to 8 , wherein the dose is about 30 μg/kg patient body weight.

10 . The method of any one of claims 6 - 9 , wherein the anti-CD40 antibody is administered every three weeks or every six weeks.

11 . The method of any one of claims 6 - 10 , further comprising administering a chemotherapeutic agent.

12 . The method of claim 11 , wherein the chemotherapeutic agent is gemcitabine, dacarbazine, temozolomide, paclitaxel, albumin-bound paclitaxel, carboplatin, or paclitaxel.

13 . The method of any one of claims 6 - 12 comprising administering 1) an anti-CD40 antibody and 2) an anti-PD1 antibody.

14 . The method of claim 13 , wherein the anti-PD1 antibody is pembrolizumab.

15 . The method of claim 13 or 14 , wherein the anti-PD1 antibody is administered at about 200 mg/kg.